Just 14 stocks with market caps above $1 billion have doubled so far this year. They probably aren't the winners you would ...

The acquisition expands Lilly’s pain pipeline with a slate of drugs targeting ion channel proteins like NaV1.7 and NaV1.8.

With VKTX surging on clinical results and NVO investing to cement market share, investors face a high-stake GLP-1 showdown.

New data from digital marketing agency Sagapixel reveals that public interest in the term “GLP-1” has officially surpassed search volume for “Ozempic” — marking a fundamental shift in how patients ...

Research even suggests it can change users' sense of smell, and other common side effects include diarrhoea, nausea, 'sulphur ...

Whichever way the tariff winds blow (and I've no special knowledge of that), Novo Nordisk stock remains arguably the cheapest ...

PolyPeptide Group, the Swiss drug ingredients manufacturer, has exercised an option to increase its revolving credit facility ...

This transition reflects a planned and strategic evolution of MC2 Therapeutics, aligned with the company’s focus on commercial expansion.

An international study reveals that the drug can reverse liver damage in patients. An international study led by researchers ...

Once swallowed, the pill expands to form a rigid triangle, mimicking the presence of food and triggering the sensation of satiety. The device remains in the stomach for several hours before passing ...

Despite Lars Fruergaard Jørgensen's resignation as Novo Nordisk's CEO, its stock price has risen 10% over the past two weeks.

Should Ozempic be added to the water supply? That is the kind of half-joking question that doctors kick around when a new ...